@jasonlukemd.bsky.social
Nature research paper: Humoral determinants of checkpoint immunotherapy
go.nature.com/41a8fin
Podcast alert! Enjoyed discussing #ASCO25 #Immunotherapy & #Melanoma data w Dr. Diwakar Davar. Important studies that are advancing the field! @ascocancer.bsky.social
dailynews.ascopubs.org/do/podcast-i...
The CheckPoints are ready to party - join us tonight Sunday June 1 at Buddy Guys! Best party of #ASCO25 & all for the great cause of the @sitcancer.bsky.social Forward Fund that supports post-doc & trainee awards. See you tonight!!!
01.06.2025 15:03 — 👍 3 🔁 0 💬 0 📌 0
Time for the #AACR25 Annual Reception, featuring the #Checkpoints! Be there tonight 830 PM at McCormick Place West (Level 3) in the Skyline Ballroom (W375). We have a bunch of new tunes & rehearsal was great! @theaacr.bsky.social
27.04.2025 12:43 — 👍 3 🔁 0 💬 0 📌 0
Excited to help lead Phase 2/3 frontline metastatic #melanoma TeLuRide-006 study of pembro +/- novel IV TLR7/8 agonist EIK1001. Super interesting pre-clinical & prelim responses in PD1 refractory dz. Trial is open in #Pittsburgh & globally for accrual!
clinicaltrials.gov/study/NCT066...
VIP tickets are available now! The CheckPoints will be back in Chicago on June 1 at Buddy Guy’s Legends. Donations will support SITC’s Forward Fund and benefit the next generation of cancer immunotherapy experts. LEARN MORE: www.sitcancer.org/funding/the-... #RockinForACure
18.04.2025 19:55 — 👍 0 🔁 1 💬 0 📌 0
Talking IMA203 & SUPRAME trial #iwCART25 in Miami last wknd. Pass the word to #melanoma patients needing novel therapeutics. After ICI, this therapy has possibility for long-term dz control! Trial opening in USA & Europe. 1st pt got IMA203 in Pittsburgh last week!
clinicaltrials.gov/study/NCT067...
Extremely excited re: IMA203 - PRAME TCR T cells Ph 1 study published in @natmedicine.bsky.social! This is a transformative Rx in #melanoma for HLA-A201+ & PD1 refractory pts. Compared to TIL, easier to make, less toxic & so far ~2x response rate in heavily pre-Rx.
www.nature.com/articles/s41...
A @sitcancer.bsky.social vision statement on accelerating #clinicaltrials to get 100 immunotherapy regulatory approvals in 10 years. Excited to be part of this effort for the paper, for our field but most importantly for the people with #cancer we are working to #cure!
jitc.bmj.com/content/13/3...
Tx @theaacr.bsky.social for highlighting our SITC #Checkpoints performance rocking the #AACR25 annual reception in Chicago - Sunday, April 27. The best #cancer science & the best party! Hope everyone will be there! @patrickhwumd.bsky.social @ferranprat.bsky.social
www.aacr.org/blog/2025/03...
and we provide some broader #biotech #bioblue context
www.sugarconebiotech.com/insights/pd1...
Nature research paper: Spatial immune scoring system predicts hepatocellular carcinoma recurrence
https://go.nature.com/3Dr0HiQ
Amazing @sitcancer.bsky.social Spring Scientific on cell therapy in solid tumors! Appreciated op to discuss IMA203. One of the hottest agents in #melanoma & perhaps all of solid tumor oncology! Very excited that the SUPRAME Ph 3 study is now accruing pts!
clinicaltrials.gov/study/NCT067...
New Journal for ImmunoTherapy of Cancer ( #JITC ) short report: Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors bit.ly/43bFMuy @jasonlukemd.bsky.social @news.upmc.com @djpinato.bsky.social
#OncSky #CanSky #research
Enjoyed discussing LAG3 targeting #melanoma w
@drbetofmdphd.bsky.social Major role for relatlimab while fianlimab data look as good/better so far! Field has been waiting long time for RELA-098 but Ph3 studies abound for cemi-fian metastatic, adjuvant and peri-op!
www.medscape.org/viewarticle/...
Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids - @pennmedicine.bsky.social go.nature.com/3EkClak
05.02.2025 14:26 — 👍 21 🔁 6 💬 2 📌 2🚀 Exciting news! The brand-new #Y2025 #SITC
#CompIO Webinar Series is here!!! 🎉
Ten courses focusing on advanced methods and clinical utility for #biomarker #development in IO @sitcancer.bsky.social @roswellpark.bsky.social #NCI 👏
✨ FREE registration: tinyurl.com/3863jp9t
Let's spread the word!🚀
Integrating #clinical, #pathological, #radiological, #transcriptomic data boosts prediction of #firstline #immunotherapy outcomes in metastatic #NSCLC 🚀
✨317 patients, PET/CT, bulk RNAseq, digitized pathology => #Multimodal #AI outperform traditional methods!
t.co/MfMNwuZaG9
Excited to speak @sitcancer.bsky.social Spring Scientific: Cellular Therapy for Solid Tumors - March 12–14, San Diego. I'll discuss Development, Clinical Efficacy & Translational Analysis of PRAME Targeting with TCR Transduced T cells via IMA203. Please join us!
www.sitcancer.org/education/sp...
Cellular RNAs directly regulate the activity of an antiviral immune signaling complex
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
@science.org @nandangokhale.bsky.social @ramlabuw.bsky.social
Appreciated interview @oncodaily.bsky.social to discuss trends in cancer #immunotherapy, my work, as well as the role of professional societies & mentorship in career development. Focus on what you are passionate about, find great mentors & GRIND! Happy holidays!
www.youtube.com/watch?v=HZqA...
Looking forward to moderating this @sitcancer.bsky.social Deep Dive into Co-stim along w Taha Mergoub featuring 3 tremendous talks from rising stars Mohamad Hamieh, Juan Osorio & Roberta Zappasodi covering novel strategies, ICI combos & CART. Please register & join us!
sitcancer.org/education/we...
Thanks #ASCO for this recognition as a Fellow! Its an honor contributing to ASCO's important work for patients, providers & the health care community. Onward then in conquering #cancer via research, ed & the highest quality, equitable patient care! See you #ASCO25!
society.asco.org/about-asco/a...
